Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seaweed weight-loss product

This article was originally published in The Tan Sheet

Executive Summary

A patent-pending extract of fucoxanthin, a compound found in brown seaweed, demonstrates significant weight loss in obese women, according to results of a double-blind, placebo-controlled study of 140 obese females. Specialty Nutrition Group's LipoxanThin product showed "significant reduction in liver fat, body fat and body weight versus placebo after 16 weeks," Sergey Grachev, MD, Professor of Medicine, First Medical Academy and Institute of Immunopathology, Russian Academy of Natural Sciences, et al., state. The study is pending publication by the Russian Academy of Natural Sciences. A recent Japanese study also demonstrating promising results for the fat-fighting effects of fucoxanthin (1"The Tan Sheet" Sept. 18, 2006, p. 11)...

You may also be interested in...



Nutraceutical R&D In Brief

Vitamin D and pancreatic cancer: Vitamin D supplementation cuts the risk of pancreatic cancer nearly in half, according to a study in the September Cancer Epidemiology Biomarkers & Prevention. Halcyon Skinner, PhD, Feinberg School of Medicine, Northwestern University, et al., find that taking the U.S. recommended daily allowance of vitamin D (400 IU) reduces the risk of pancreatic cancer by 43%. Those who consume less than 150 IU/day experience a 22% reduced risk of cancer. No significant benefit was found for those consuming more than 400 IU/day. Skinner et al. analyzed data on 46,771 men age 40-75 and 75,427 women age 38-65. The authors recommend further research to determine whether vitamin D ingestion from dietary sources is preferable to multivitamin supplementation. Some multivitamins contain retinol, an antagonist that influences vitamin D's ability to affect mineral balances and bone integrity, Skinner et al. note...

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel